Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Accumulated Expenses (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Accumulated Expenses for 14 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 42.31% to $2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.3 million, a 42.31% decrease, with the full-year FY2025 number at $38.2 million, changed 0.06% from a year prior.
  • Accumulated Expenses was $2.3 million for Q4 2025 at Aytu Biopharma, down from $4.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $49.6 million in Q1 2023 to a low of $2.3 million in Q4 2025.
  • A 5-year average of $16.4 million and a median of $5.3 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: soared 843.04% in 2023, then plummeted 92.15% in 2024.
  • Aytu Biopharma's Accumulated Expenses stood at $5.0 million in 2021, then soared by 717.66% to $41.2 million in 2022, then grew by 5.33% to $43.4 million in 2023, then tumbled by 90.85% to $4.0 million in 2024, then crashed by 42.31% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Accumulated Expenses are $2.3 million (Q4 2025), $4.0 million (Q3 2025), and $38.2 million (Q2 2025).